The generation of pulsed electric fields for tissue therapeutics has moved from the laboratory to clinical applications over the past two decades, while the effects of brief pulses of high voltages and large electric fields on tissue have been investigated for the past forty years or more. Application of brief high DC voltages to tissue, which can generate locally high electric fields typically in the range of hundreds of Volts/centimeter, can disrupt cell membranes by generating pores in the cell membrane. While the precise mechanism of this electrically-driven pore generation or electroporation is unclear, it is thought that the application of relatively large electric fields generates instabilities in the lipid bilayers in cell membranes, causing the occurrence of a distribution of local gaps or pores in the membrane. If the applied electric field at the membrane is larger than a threshold value, the electroporation can be irreversible and the pores remain open, permitting exchange of biomolecular material across the membrane and leading to necrosis and/or apoptosis (cell death). Subsequently the surrounding tissue heals in a natural process.
Hence, known electroporation applications in medicine and delivery methods do not address high voltage application, tissue selectivity, and safe energy delivery, especially in the context of ablation therapy for cardiac arrhythmias with catheter devices. Further, there is an unmet need for thin, flexible, atraumatic devices that can at the same time effectively deliver high DC voltage electroporation ablation therapy selectively to tissue in regions of interest while minimizing damage to healthy tissue, and for a combination of device design and dosing waveform that involves minimal or no device repositioning, permitting an effective, safe and rapid clinical procedure.
A system includes a pulse waveform generator and an ablation device coupled to the pulse waveform generator. The ablation device includes at least one electrode configured for ablation pulse delivery to tissue during use. The pulse waveform generator is configured to deliver voltage pulses to the ablation device in the form of a pulsed waveform. A first level of a hierarchy of the pulsed waveform includes a first set of pulses, each pulse having a pulse time duration, with a first time interval separating successive pulses. A second level of the hierarchy of the pulsed waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval.
The terms “about” and “approximately” as used herein in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication. For example, the language “about 50” units or “approximately 50” units means from 45 units to 55 units.
In some embodiments, a system includes a pulse waveform generator and an ablation device coupled to the pulse waveform generator. The ablation device includes at least one electrode configured for ablation pulse delivery to tissue during use. The pulse waveform generator is configured to deliver voltage pulses to the ablation device in the form of a pulsed waveform. A first level of a hierarchy of the pulsed waveform includes a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. A second level of the hierarchy of the pulsed waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval. A third level of the hierarchy of the pulsed waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses, the third time interval being at least 30 times the duration of the second time interval.
In some embodiments, the pulses of each first set of pulses include monophasic pulses with a voltage amplitude of at least 800 Volts. In some embodiments, the pulse time duration of each monophasic pulse is in the range from about 1 microsecond to about 300 microseconds.
In some embodiments, the pulses of each first set of pulses include biphasic pulses each with a voltage amplitude of at least 800 Volts. In some embodiments, the pulse time duration of each biphasic pulse is in the range from about 0.5 nanosecond to about 20 microseconds.
In some embodiments, each second set of pulses includes at least 2 first sets of pulses and less than 40 first sets of pulses. In some embodiments, each third set of pulses includes at least 2 second sets of pulses and less than 30 second sets of pulses. In some embodiments, the second time interval is at least ten times the pulse time duration.
In some embodiments, the ablation device includes an ablation catheter configured for epicardial placement. In some embodiments, the ablation device includes an ablation catheter configured for endocardial placement.
In some embodiments, a system includes a pulse waveform generator, and an ablation device coupled to the pulse waveform generator, the ablation device including at least one electrode configured for ablation pulse delivery to tissue during use. The pulse waveform generator is configured to deliver voltage pulses to the ablation device in the form of a pulsed waveform. A first level of a hierarchy of the pulsed waveform includes a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. A second level of the hierarchy of the pulsed waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first set of pulses. In some embodiments, the second time interval is at least three times the duration of the first time interval. A third level of the hierarchy of the pulsed waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses. In some embodiments, the third time interval is at least thirty times the duration of the second time interval. The pulse waveform generator is configured to apply a plurality of the third sets of pulses to the ablation device with a time delay of at most about 5 milliseconds between successive third sets of pulses applied over different electrode sets.
In some embodiments, the ablation device includes an ablation catheter configured for epicardial placement. In some embodiments, the ablation catheter includes at least four electrodes.
In some embodiments, each second set of pulses includes at least 2 first sets of pulses and less than 40 first sets of pulses. In some embodiments, each third set of pulses includes at least 2 second sets of pulses and less than 30 second sets of pulses. In some embodiments, the pulses of each first set of pulses has a voltage amplitude of at least 800 Volts.
In some embodiments, a system includes a pulse waveform generator and an ablation device coupled to the pulse waveform generator, the ablation device including at least one electrode configured for ablation pulse delivery to tissue during use. The system also includes a cardiac stimulator coupled to the pulse waveform generator, the cardiac stimulator configured for generating pacing signals for cardiac stimulation during use. The pulse waveform generator is configured to deliver voltage pulses to the ablation device in the form of a pulsed waveform, the pulsed waveform being in synchrony with the pacing signals. A first level of a hierarchy of the pulsed waveform includes a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. A second level of the hierarchy of the pulsed waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses. A third level of the hierarchy of the pulsed waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses. The pulse waveform generator is configured to generate the pulsed waveform such that each of the first sets of pulses and each of the second sets of pulses, the plurality of second sets of pulses, the predetermined number of electrode sets, the time delay, the pulse time duration, the first time interval, the second time interval, and the third time interval are jointly constrained by a Diophantine inequality.
In some embodiments, the Diophantine inequality constraint is further characterized by a refractory time window. In some embodiments, a number of the first sets of pulses and a number of the second sets of pulses are pre-determined.
In some embodiments, the pulse waveform generator is further configured to deliver the pulsed waveform spaced from the pacing signals by a time offset, the time offset being smaller than about 25 milliseconds. In some embodiments, the third time interval corresponds to a pacing period associated with the pacing signals. In some embodiments, the second time interval is at least three times the duration of the first time interval. In some embodiments, the third time interval is at least thirty times the duration of the second time interval. In some embodiments, the second level time interval is at least ten times the duration of the pulse time duration.
In some embodiments, the ablation device includes an ablation catheter configured for epicardial placement. In some embodiments, the ablation device includes an ablation catheter configured for endocardial placement.
In some embodiments, a system includes a pulse waveform generator including a user interface and an ablation device coupled to the pulse waveform generator, the ablation device including a plurality of electrodes configured for ablation pulse delivery to tissue of a patient during use. The system also includes a cardiac stimulator coupled to the pulse waveform generator, the cardiac stimulator configured for generating pacing signals for cardiac stimulation of the patient during use. The pulse waveform generator is configured to deliver voltage pulses to the ablation device in the form of a pulsed voltage waveform having at least three levels of hierarchy. The pulse waveform generator is further configured to deliver the pulsed voltage waveform in synchrony with the pacing signals, and to deliver the pulsed voltage waveform upon receipt of the indication of user confirmation.
In some embodiments, a first level of a hierarchy of the pulsed waveform includes a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. In some embodiments, a second level of the hierarchy of the pulsed waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses. In some embodiments, a third level of the hierarchy of the pulsed waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses. In some embodiments, the pulse waveform generator is further configured to apply a plurality of third sets of pulses to a predetermined number of electrode sets of the ablation device with a time delay between successive third sets of pulses. In some embodiments, each of the first sets of pulses and each of the second sets of pulses, the predetermined number of electrode sets, the time delay, the pulse time duration, the first time interval, the second time interval, and the third time interval are jointly constrained by a Diophantine inequality.
In some embodiments, the pulse waveform generator is configured to deliver the pulsed waveform only after a pre-determined time interval after the indication of user confirmation. In some embodiments, the user interface includes a control input device, and the pulse waveform generator is configured to deliver the pulsed waveform upon user engagement of the control input device.
In some embodiments, a method includes generating a pulsed waveform. The pulsed waveform includes a first level of a hierarchy of the pulsed waveform that includes a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. The pulse waveform also includes a second level of the hierarchy of the pulsed waveform that includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval. The pulse waveform a third level of the hierarchy of the pulsed waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses, the third time interval being at least thirty times the duration of the second level time interval. The method also includes delivering the pulsed waveform to an ablation device.
In some embodiments, a method includes generating a pulsed waveform. The pulsed waveform includes a first level of a hierarchy of the pulsed waveform that includes a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. The pulsed waveform also includes a second level of the hierarchy of the pulsed waveform that includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval. The pulsed waveform also includes a third level of the hierarchy of the pulsed waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses, the third time interval being at least thirty times the duration of the second level time interval. The method also includes generating pacing signals with a cardiac stimulator. The method also includes delivering, in synchrony with the pacing signals, the pulsed waveform to an ablation device.
Disclosed herein are methods, systems and apparatuses for the selective and rapid application of pulsed electric fields/waveforms to effect tissue ablation with irreversible electroporation. Some embodiments are directed to pulsed high voltage waveforms together with a sequenced delivery scheme for delivering energy to tissue via sets of electrodes. In some embodiments, the electrodes are catheter-based electrodes, or a plurality of electrodes disposed along the length of an elongate medical device. In some embodiments, a system useful for irreversible electroporation includes a voltage/signal generator and a controller capable of being configured to apply pulsed voltage waveforms to a selected plurality or a subset of electrodes of an ablation device. In some embodiments, the controller is configured to control inputs whereby selected pairs of anode-cathode subsets of electrodes can be sequentially triggered based on a pre-determined sequence, and in one embodiment the sequenced delivery can be triggered from a cardiac stimulator or pacing system/device. In some embodiments, the ablation pulse waveforms are applied in a refractory period of the cardiac cycle so as to avoid disruption in rhythm regularity of the heart. One example method of enforcing this is to electrically pace the heart with a cardiac stimulator and ensure pacing capture to establish periodicity and predictability of the cardiac cycle, and then to define a time window well within the refractory period of this periodic cycle within which the ablation waveform is delivered.
In some embodiments, the pulsed voltage waveforms disclosed herein are hierarchical in organization and have a nested structure. In some embodiments, the pulsed waveform includes hierarchical groupings of pulses with a variety of associated timescales. Furthermore, the associated timescales and pulse widths, and the numbers of pulses and hierarchical groupings, can be selected so as to satisfy one or more of a set of Diophantine inequalities involving the frequency of cardiac pacing.
Pulsed waveforms for electroporation energy delivery as disclosed herein can enhance the safety, efficiency and effectiveness of the energy delivery by reducing the electric field threshold associated with irreversible electroporation, yielding more effective ablative lesions with reduced total energy delivered. This in turn can broaden the areas of clinical application of electroporation including therapeutic treatment of a variety of cardiac arrhythmias.
The present disclosure addresses the need for devices and methods for rapid, selective and safe delivery of irreversible electroporation therapy, generally with multiple devices, such that, in some embodiments, peak electric field values can be reduced and/or minimized while at the same time sufficiently large electric field magnitudes can be maintained in regions where tissue ablation is desired. This also reduces the likelihood of excessive tissue damage or the generation of electrical arcing, and locally high temperature increases.
In some embodiments, the catheter electrodes 17 can be constructed in the form of metallic bands or rings. In some embodiments, each electrode 17 can be constructed so as to be flexible. For example, the electrodes 17 can be in the form of metallic coiled springs or helical windings around the shaft of the catheter 15. As another example, the electrode(s) 17 can be in the form of a series of metallic bands or rings disposed along the shaft and that are electrically connected together, with the flexible portions of catheter shaft between the electrodes providing flexibility to the entire electrode. In some embodiments, at least a portion of the electrodes 17 can include biocompatible metals such as, but not limited to, titanium, palladium, silver, platinum and/or platinum alloys. In some embodiments, at least a portion of the electrodes 17 includes platinum and/or platinum alloys. In some embodiments, the catheter shaft can be made of a flexible polymeric material such as (for purposes of non-limiting examples only) polytetrafluorethylene, polyamides such as nylon, or polyether block amide. The electrodes 17 can be connected to insulated electrical leads (not shown) leading to a proximal handle portion of the catheter 15 (not shown), with the insulation on each of the leads being capable of sustaining an electrical potential difference of at least 700V across its thickness without dielectric breakdown. While the catheter 15 is placed epicardially as shown in
Embodiments disclosed herein include waveforms structured as hierarchical waveforms that include waveform elements/pulses at various levels of the hierarchy. The individual pulses such as 115 in
In some embodiments, hierarchical waveforms with a nested structure and hierarchy of time intervals as described herein are useful for irreversible electroporation ablation energy delivery, providing a good degree of control and selectivity for applications in different tissue types. A variety of hierarchical waveforms can be generated with a suitable pulse generator. It is understood that while the examples herein identify separate monophasic and biphasic waveforms for clarity, it should be noted that combination waveforms, where some portions of the waveform hierarchy are monophasic while other portions are biphasic, can also be generated/implemented.
In embodiments directed to treatment of cardiac ablation, the pulse waveforms described above can be applied with electrode bipoles selected from a set of electrodes on a catheter, such as an ablation catheter. A subset of electrodes of the catheter can be chosen as anodes, while another subset of electrodes of the ablation catheter can be chosen as cathodes, with the voltage waveform being applied between anodes and cathodes. As a non-limiting example, in instances where the ablation catheter is an epicardially placed ablation catheter, the catheter can be wrapped around the pulmonary veins, and one electrode can be chosen as anode and another electrode can be chosen as cathode.
In some embodiments, the ablation pulse waveforms described herein are applied during the refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. In some embodiments, a method of treatment includes electrically pacing the heart with a cardiac stimulator to ensure pacing capture to establish periodicity and predictability of the cardiac cycle, and then defining a time window within the refractory period of the cardiac cycle within which one or more pulsed ablation waveforms can be delivered.
A timing sequence of electrode activation over a series of electrode sets is illustrated in
j[m2(m1w+t1(m1−1))+t2(m2−1)]+td(j−1)<Tr (1)
that the pulse waveform parameters m1 and m2 must satisfy for a given number of electrode sets j, in order for the entire ablation pulse delivery to occur within a refractory time window Tr. In some embodiments, the refractory time window Tr can be about 140 milliseconds or less. The time offset of the start of the refractory window with respect to a pacing signal can be less than about 10 milliseconds. While the time intervals w, t1, t2 and td can be arbitrary, when implemented with finite state machines such as (for example) a computer processor, they are integers as measured in some suitable units (such as, for example, microseconds, nanoseconds or multiples of a fundamental processor clock time period). Given a number of electrode sets j, equation (1) represents a Diophantine inequality mutually constraining the pulse waveform parameters (pulse width, time intervals and numbers of pulses and groups) such that the total duration of the waveform application over the j electrode sets is smaller than a given common refractory period. In some embodiments, a solution set for the Diophantine inequality can be found based on partial constraints on the pulse waveform parameters. For example, the generator can require input of some of the pulse waveform parameters and/or related parameters, for example the pulse width w and time delay td, after which the system console determines the rest of the pulse waveform parameters. In this case the number of electrode sets j is also an input to the system that constrains the solution determination. In one embodiment the system console could display more than one such possible solution set of waveform parameters for the user to make a selection, while in an alternate embodiment the system makes an automatic selection or determination of the waveform parameters. In some embodiments, a solution can be calculated and directly implemented in pre-determined form, such as, for example, on a pulse generator system console. For example, all of the pulse waveform parameters are pre-determined to satisfy a Diophantine inequality similar to equation (1) and the waveform is pre-programmed on the system; possibly the pre-determined solution(s) can depend on the number of electrode sets j, or alternately the solution(s) can be pre-determined assuming a maximal number for the electrode sets. In some embodiments more than one solution could be pre-determined and made available for user selection on the system console.
While the Diophantine inequality (1) holds for delivery of a single waveform packet over a single refractory time window, the full waveform can sometimes involve a plurality of packets. The number of packets can be pre-determined and in one embodiment can range from 1 to 28 packets, including all values and sub ranges in between. The appropriate refractory time window Tr can be pre-determined and/or pre-defined in one embodiment or, in an alternate embodiment, it can be selected by a user from within a certain pre-determined range. While inequality (1) was explicitly written for a monophasic hierarchical waveform, a similar inequality may be written for a biphasic waveform, or for a waveform that combines monophasic and biphasic elements.
A schematic illustration of ablation waveform delivery over multiple electrode sets j with a series of packets at the top level of the waveform hierarchy is provided in
In some embodiments, the complete sequence of electrode sets can be subdivided into smaller subsequences of electrode sets/electrode subsets. For example, the complete sequence of j electrode sets can be subdivided into N subsequences with j1 electrode sets in the first subsequence/first subset, j2 electrode sets in the second subsequence/second subset, and so on, with jN electrode sets in the N-th subsequence. The waveform packets are applied first over the first subsequence of j1 electrode sets, then over the second subsequence of j2 electrode sets, and so on, with cardiac pacing employed throughout and all waveform packets applied within appropriate refractory time windows.
In some embodiments, the system 200 can also include a memory and/or a database (not shown) configured for, for example, storing pacing data, waveform information, and/or the like. The memory and/or the database can independently be, for example, a random access memory (RAM), a memory buffer, a hard drive, a database, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), Flash memory, and/or so forth. The memory and/or the database can store instructions to cause the generator/controller 202 to execute modules, processes and/or functions associated with the system 200, such as pulsed waveform generation and/or cardiac pacing.
The system 200 can be in communication with other devices (not shown) via, for example, one or more networks, each of which can be any type of network such as, for example, a local area network (LAN), a wide area network (WAN), a virtual network, a telecommunications network, and/or the Internet, implemented as a wired network and/or a wireless network. Any or all communications can be secured (e.g., encrypted) or unsecured, as is known in the art. The system 200 can include and/or encompass a personal computer, a server, a work station, a tablet, a mobile device, a cloud computing environment, an application or a module running on any of these platforms, and/or the like.
The system console 215 delivers ablation pulses to an ablation catheter 209 that is suitably positioned in a patient anatomy such as, for example, in a loop around the patient's pulmonary veins in a pericardial space of the patient's heart. An intracardiac ECG recording and pacing catheter 212 is coupled to an ECG recording system 208 via the connection box 210. The ECG recording system 208 is connected to a cardiac stimulator or pacing unit 207. The cardiac stimulator 207 can send a pacing output to the recording and pacing catheter 212; in general both atrial and ventricular pacing signals can be generated as outputs from the cardiac stimulator 207, and in some embodiments there can be separate intracardiac atrial and ventricular pacing catheters (not shown) or leads, each of which can then be disposed and/or positioned in the appropriate cardiac chamber. The same pacing output signal is also sent to the ablation system console 215. The pacing signal is received by the ablation system console and, based on the pacing signal, the ablation waveform can be generated by the generator/controller 202 within a common refractory window as described herein. In some embodiments, the common refractory window can start substantially immediately following the ventricular pacing signal (or after a very small delay) and last for a duration of approximately 130 ms or less thereafter. In this case, the entire ablation waveform packet is delivered within this duration, as explained earlier.
The user interface 203 associated with the ablation system console 215 can be implemented in a variety of forms as convenient for the application. When an epicardial ablation catheter is delivered via a subxiphoid approach and is placed epicardially around the pulmonary veins as shown in
As shown in
As shown in
The waveform parameters as detailed herein can be determined by the design of the signal generator, and in some embodiments the parameters can be pre-determined. In some embodiments, at least a subset of the waveform parameters could be determined by user control as may be convenient for a given clinical application. The specific examples and descriptions herein are exemplary in nature and variations can be developed by those skilled in the art based on the material taught herein without departing from the scope of embodiments disclosed herein.
One or more embodiments described herein relate to a computer storage product with a non-transitory computer-readable medium (also can be referred to as a non-transitory processor-readable medium) having instructions or computer code thereon for performing various computer-implemented operations. The computer-readable medium (or processor-readable medium) is non-transitory in the sense that it does not include transitory propagating signals per se (e.g., a propagating electromagnetic wave carrying information on a transmission medium such as space or a cable). The media and computer code (also can be referred to as code or algorithm) may be those designed and constructed for the specific purpose or purposes. Examples of non-transitory computer-readable media include, but are not limited to, magnetic storage media such as hard disks, floppy disks, and magnetic tape; optical storage media such as Compact Disc/Digital Video Discs (CD/DVDs), Compact Disc-Read Only Memories (CD-ROMs), and holographic devices; magneto-optical storage media such as optical disks; carrier wave signal processing modules; and hardware devices that are specially configured to store and execute program code, such as Application-Specific Integrated Circuits (ASICs), Programmable Logic Devices (PLDs), Read-Only Memory (ROM) and Random-Access Memory (RAM) devices. Other embodiments described herein relate to a computer program product, which can include, for example, the instructions and/or computer code disclosed herein.
One or more embodiments and/or methods described herein can be performed by software (executed on hardware), hardware, or a combination thereof. Hardware modules may include, for example, a general-purpose processor (or microprocessor or microcontroller), a field programmable gate array (FPGA), and/or an application specific integrated circuit (ASIC). Software modules (executed on hardware) can be expressed in a variety of software languages (e.g., computer code), including C, C++, Java®, Ruby, Visual Basic®, and/or other object-oriented, procedural, or other programming language and development tools. Examples of computer code include, but are not limited to, micro-code or micro-instructions, machine instructions, such as produced by a compiler, code used to produce a web service, and files containing higher-level instructions that are executed by a computer using an interpreter. Additional examples of computer code include, but are not limited to, control signals, encrypted code, and compressed code.
While various embodiments have been described above, it should be understood that they have been presented by way of example, and not limitation. Where methods described above indicate certain events occurring in certain order, the ordering of certain events can be modified. Additionally, certain of the events may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above
This application is a divisional of U.S. patent application Ser. No. 15/334,646 titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE”, filed Oct. 26, 2016, now abandoned, which is a continuation of PCT Application No. PCT/US2016/057664 titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE”, filed Oct. 19, 2016, NOW Abandoned, which claims priority to U.S. Provisional Application No. 62/274,926 titled “METHOD AND APPARATUS FOR DELIVERY OF PULSED ELECTRIC FIELD ABLATIVE ENERGY TO TISSUE”, filed Jan. 5, 2016, the entire disclosures of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4470407 | Hussein | Sep 1984 | A |
5242441 | Avitall | Sep 1993 | A |
5257635 | Langberg | Nov 1993 | A |
5281213 | Milder et al. | Jan 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5342301 | Saab | Aug 1994 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5454370 | Avitall | Oct 1995 | A |
5515848 | Corbett, III et al. | May 1996 | A |
5531685 | Hemmer et al. | Jul 1996 | A |
5545161 | Imran | Aug 1996 | A |
5617854 | Munsif | Apr 1997 | A |
5624430 | Eton et al. | Apr 1997 | A |
5667491 | Pliquett et al. | Sep 1997 | A |
5672170 | Cho | Sep 1997 | A |
5700243 | Narciso, Jr. | Dec 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5706823 | Wodlinger | Jan 1998 | A |
5722400 | Ockuly et al. | Mar 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5749914 | Janssen | May 1998 | A |
5779699 | Lipson | Jul 1998 | A |
5788692 | Campbell et al. | Aug 1998 | A |
5810762 | Hofmann | Sep 1998 | A |
5833710 | Jacobson | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5836942 | Netherly et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5843154 | Osypka | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5863291 | Schaer | Jan 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5895404 | Ruiz | Apr 1999 | A |
5899917 | Edwards et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5916158 | Webster, Jr. | Jun 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5921924 | Avitall | Jul 1999 | A |
5928269 | Alt | Jul 1999 | A |
5928270 | Ramsey, III | Jul 1999 | A |
6002955 | Willems et al. | Dec 1999 | A |
6006131 | Cooper et al. | Dec 1999 | A |
6009351 | Flachman | Dec 1999 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6033403 | Tu et al. | Mar 2000 | A |
6045550 | Simpson et al. | Apr 2000 | A |
6068653 | LaFontaine | May 2000 | A |
6071274 | Thompson et al. | Jun 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6090104 | Webster, Jr. | Jul 2000 | A |
6096036 | Bowe et al. | Aug 2000 | A |
6113595 | Muntermann | Sep 2000 | A |
6119041 | Pomeranz et al. | Sep 2000 | A |
6120500 | Bednarek et al. | Sep 2000 | A |
6146381 | Bowe et al. | Nov 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6167291 | Barajas et al. | Dec 2000 | A |
6216034 | Hofmann et al. | Apr 2001 | B1 |
6219582 | Hofstad et al. | Apr 2001 | B1 |
6223085 | Dann et al. | Apr 2001 | B1 |
6231518 | Grabek et al. | May 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6251107 | Schaer | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6272384 | Simon et al. | Aug 2001 | B1 |
6287306 | Kroll et al. | Sep 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6350263 | Wetzig et al. | Feb 2002 | B1 |
6370412 | Armoundas et al. | Apr 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6447505 | McGovern et al. | Sep 2002 | B2 |
6464699 | Swanson | Oct 2002 | B1 |
6470211 | Ideker et al. | Oct 2002 | B1 |
6502576 | Lesh | Jan 2003 | B1 |
6503247 | Swartz et al. | Jan 2003 | B2 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6527724 | Fenici | Mar 2003 | B1 |
6527767 | Wang et al. | Mar 2003 | B2 |
6592581 | Bowe | Jul 2003 | B2 |
6595991 | Tollner et al. | Jul 2003 | B2 |
6607520 | Keane | Aug 2003 | B2 |
6623480 | Kuo et al. | Sep 2003 | B1 |
6638278 | Falwell et al. | Oct 2003 | B2 |
6666863 | Wentzel et al. | Dec 2003 | B2 |
6669693 | Friedman | Dec 2003 | B2 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6719756 | Muntermann | Apr 2004 | B1 |
6723092 | Brown et al. | Apr 2004 | B2 |
6728563 | Rashidi | Apr 2004 | B2 |
6743225 | Sanchez et al. | Jun 2004 | B2 |
6743239 | Kuehn et al. | Jun 2004 | B1 |
6764486 | Natale | Jul 2004 | B2 |
6780181 | Kroll et al. | Aug 2004 | B2 |
6805128 | Pless | Oct 2004 | B1 |
6807447 | Griffin, III | Oct 2004 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6893438 | Hall et al. | May 2005 | B2 |
6926714 | Sra | Aug 2005 | B1 |
6955173 | Lesh | Oct 2005 | B2 |
6960206 | Keane | Nov 2005 | B2 |
6960207 | Vanney et al. | Nov 2005 | B2 |
6972016 | Hill, III et al. | Dec 2005 | B2 |
6973339 | Govari | Dec 2005 | B2 |
6979331 | Hintringer et al. | Dec 2005 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
6985776 | Kane et al. | Jan 2006 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7041095 | Wang et al. | May 2006 | B2 |
7171263 | Darvish et al. | Jan 2007 | B2 |
7182725 | Bonan et al. | Feb 2007 | B2 |
7195628 | Falkenberg | Mar 2007 | B2 |
7207988 | Leckrone et al. | Apr 2007 | B2 |
7207989 | Pike, Jr. et al. | Apr 2007 | B2 |
7229402 | Diaz et al. | Jun 2007 | B2 |
7229437 | Johnson et al. | Jun 2007 | B2 |
7250049 | Roop et al. | Jul 2007 | B2 |
7285116 | de la Rama et al. | Oct 2007 | B2 |
7285119 | Stewart et al. | Oct 2007 | B2 |
7326208 | Vanney et al. | Feb 2008 | B2 |
7346379 | Eng et al. | Mar 2008 | B2 |
7367974 | Haemmerich et al. | May 2008 | B2 |
7374567 | Heuser | May 2008 | B2 |
7387629 | Vanney et al. | Jun 2008 | B2 |
7387630 | Mest | Jun 2008 | B2 |
7387636 | Cohn et al. | Jun 2008 | B2 |
7416552 | Paul et al. | Aug 2008 | B2 |
7419477 | Simpson et al. | Sep 2008 | B2 |
7419489 | Vanney et al. | Sep 2008 | B2 |
7429261 | Kunis et al. | Sep 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7513896 | Orszulak | Apr 2009 | B2 |
7527625 | Knight et al. | May 2009 | B2 |
7578816 | Boveja et al. | Aug 2009 | B2 |
7588567 | Boveja et al. | Sep 2009 | B2 |
7623899 | Worley et al. | Nov 2009 | B2 |
7678108 | Chrisitian et al. | Mar 2010 | B2 |
7681579 | Schwartz | Mar 2010 | B2 |
7771421 | Stewart et al. | Aug 2010 | B2 |
7805182 | Weese et al. | Sep 2010 | B2 |
7850642 | Moll et al. | Dec 2010 | B2 |
7850685 | Kunis et al. | Dec 2010 | B2 |
7857808 | Oral et al. | Dec 2010 | B2 |
7857809 | Drysen | Dec 2010 | B2 |
7869865 | Govari et al. | Jan 2011 | B2 |
7896873 | Hiller et al. | Mar 2011 | B2 |
7917211 | Zacouto | Mar 2011 | B2 |
7918819 | Karmarkar et al. | Apr 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7922714 | Stevens-Wright | Apr 2011 | B2 |
7955827 | Rubinsky et al. | Jun 2011 | B2 |
8048067 | Davalos et al. | Nov 2011 | B2 |
8048072 | Verin et al. | Nov 2011 | B2 |
8100895 | Panos et al. | Jan 2012 | B2 |
8100900 | Prinz et al. | Jan 2012 | B2 |
8108069 | Stahler et al. | Jan 2012 | B2 |
8133220 | Lee et al. | Mar 2012 | B2 |
8137342 | Crossman | Mar 2012 | B2 |
8145289 | Calabro′ et al. | Mar 2012 | B2 |
8147486 | Honour et al. | Apr 2012 | B2 |
8160690 | Wilfley et al. | Apr 2012 | B2 |
8175680 | Panescu | May 2012 | B2 |
8182477 | Orszulak et al. | May 2012 | B2 |
8206384 | Falwell et al. | Jun 2012 | B2 |
8206385 | Stangenes et al. | Jun 2012 | B2 |
8216221 | Ibrahim et al. | Jul 2012 | B2 |
8221411 | Francischelli et al. | Jul 2012 | B2 |
8226648 | Paul et al. | Jul 2012 | B2 |
8228065 | Wirtz et al. | Jul 2012 | B2 |
8235986 | Kulesa et al. | Aug 2012 | B2 |
8235988 | Davis et al. | Aug 2012 | B2 |
8251986 | Chornenky et al. | Aug 2012 | B2 |
8282631 | Davalos et al. | Oct 2012 | B2 |
8287532 | Carroll et al. | Oct 2012 | B2 |
8414508 | Thapliyal et al. | Apr 2013 | B2 |
8430875 | Ibrahim et al. | Apr 2013 | B2 |
8433394 | Harlev et al. | Apr 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8454594 | Demarais et al. | Jun 2013 | B2 |
8463368 | Harlev et al. | Jun 2013 | B2 |
8475450 | Govari et al. | Jul 2013 | B2 |
8486063 | Werneth et al. | Jul 2013 | B2 |
8500733 | Watson | Aug 2013 | B2 |
8535304 | Sklar et al. | Sep 2013 | B2 |
8538501 | Venkatachalam et al. | Sep 2013 | B2 |
8562588 | Hobbs et al. | Oct 2013 | B2 |
8568406 | Harlev et al. | Oct 2013 | B2 |
8571635 | McGee | Oct 2013 | B2 |
8571647 | Harlev et al. | Oct 2013 | B2 |
8585695 | Shih | Nov 2013 | B2 |
8588885 | Hall et al. | Nov 2013 | B2 |
8597288 | Christian | Dec 2013 | B2 |
8608735 | Govari et al. | Dec 2013 | B2 |
8628522 | Ibrahim et al. | Jan 2014 | B2 |
8632534 | Pearson et al. | Jan 2014 | B2 |
8647338 | Chornenky et al. | Feb 2014 | B2 |
8708952 | Cohen et al. | Apr 2014 | B2 |
8734442 | Cao et al. | May 2014 | B2 |
8771267 | Kunis et al. | Jul 2014 | B2 |
8795310 | Fung et al. | Aug 2014 | B2 |
8808273 | Caples et al. | Aug 2014 | B2 |
8834461 | Werneth et al. | Sep 2014 | B2 |
8834464 | Stewart et al. | Sep 2014 | B2 |
8868169 | Narayan et al. | Oct 2014 | B2 |
8876817 | Avitall et al. | Nov 2014 | B2 |
8886309 | Luther et al. | Nov 2014 | B2 |
8903488 | Callas et al. | Dec 2014 | B2 |
8920411 | Gelbart et al. | Dec 2014 | B2 |
8926589 | Govari | Jan 2015 | B2 |
8932287 | Gelbart et al. | Jan 2015 | B2 |
8945117 | Bencini | Feb 2015 | B2 |
8979841 | Kunis et al. | Mar 2015 | B2 |
8986278 | Fung et al. | Mar 2015 | B2 |
9002442 | Harley et al. | Apr 2015 | B2 |
9005189 | Davalos et al. | Apr 2015 | B2 |
9005194 | Oral et al. | Apr 2015 | B2 |
9011425 | Fischer et al. | Apr 2015 | B2 |
9044245 | Condie et al. | Jun 2015 | B2 |
9055959 | Vaska et al. | Jun 2015 | B2 |
9072518 | Swanson | Jul 2015 | B2 |
9078667 | Besser et al. | Jul 2015 | B2 |
9101374 | Hoch et al. | Aug 2015 | B1 |
9119533 | Ghaffari | Sep 2015 | B2 |
9119634 | Gelbart et al. | Sep 2015 | B2 |
9131897 | Harada et al. | Sep 2015 | B2 |
9155590 | Mathur | Oct 2015 | B2 |
9162037 | Belson et al. | Oct 2015 | B2 |
9179972 | Olson | Nov 2015 | B2 |
9186481 | Avitall et al. | Nov 2015 | B2 |
9192769 | Donofrio et al. | Nov 2015 | B2 |
9211405 | Mahapatra et al. | Dec 2015 | B2 |
9216055 | Spence et al. | Dec 2015 | B2 |
9233248 | Luther et al. | Jan 2016 | B2 |
9237926 | Nollert et al. | Jan 2016 | B2 |
9262252 | Kirkpatrick et al. | Feb 2016 | B2 |
9277957 | Long et al. | Mar 2016 | B2 |
9282910 | Narayan et al. | Mar 2016 | B2 |
9289258 | Cohen | Mar 2016 | B2 |
9289606 | Paul et al. | Mar 2016 | B2 |
9295516 | Pearson et al. | Mar 2016 | B2 |
9301801 | Scheib | Apr 2016 | B2 |
9375268 | Long | Jun 2016 | B2 |
9414881 | Callas et al. | Aug 2016 | B2 |
9468495 | Kunis et al. | Oct 2016 | B2 |
9474486 | Eliason et al. | Oct 2016 | B2 |
9474574 | Ibrahim et al. | Oct 2016 | B2 |
9480525 | Lopes et al. | Nov 2016 | B2 |
9486272 | Bonyak et al. | Nov 2016 | B2 |
9486273 | Lopes et al. | Nov 2016 | B2 |
9492227 | Lopes et al. | Nov 2016 | B2 |
9492228 | Lopes et al. | Nov 2016 | B2 |
9517103 | Panescu et al. | Dec 2016 | B2 |
9526573 | Lopes et al. | Dec 2016 | B2 |
9532831 | Reinders et al. | Jan 2017 | B2 |
9539010 | Gagner et al. | Jan 2017 | B2 |
9554848 | Stewart et al. | Jan 2017 | B2 |
9554851 | Sklar et al. | Jan 2017 | B2 |
9700368 | Callas et al. | Jul 2017 | B2 |
9724170 | Mickelsen | Aug 2017 | B2 |
9757193 | Zarins et al. | Sep 2017 | B2 |
9782099 | Williams et al. | Oct 2017 | B2 |
9795442 | Salahieh et al. | Oct 2017 | B2 |
9861802 | Mickelsen | Jan 2018 | B2 |
9913685 | Clark et al. | Mar 2018 | B2 |
9931487 | Quinn et al. | Apr 2018 | B2 |
9987081 | Bowers et al. | Jun 2018 | B1 |
9999465 | Long et al. | Jun 2018 | B2 |
10016232 | Bowers et al. | Jul 2018 | B1 |
10130423 | Viswanathan et al. | Nov 2018 | B1 |
10172673 | Viswanathan et al. | Jan 2019 | B2 |
20010007070 | Stewart et al. | Jul 2001 | A1 |
20010044624 | Seraj et al. | Nov 2001 | A1 |
20020052602 | Wang et al. | May 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020111618 | Stewart et al. | Aug 2002 | A1 |
20020161323 | Miller et al. | Oct 2002 | A1 |
20020169445 | Jain et al. | Nov 2002 | A1 |
20020177765 | Bowe et al. | Nov 2002 | A1 |
20020183638 | Swanson | Dec 2002 | A1 |
20030014098 | Quijano et al. | Jan 2003 | A1 |
20030018374 | Paulos | Jan 2003 | A1 |
20030028189 | Woloszko et al. | Feb 2003 | A1 |
20030050637 | Maguire et al. | Mar 2003 | A1 |
20030114849 | Ryan | Jun 2003 | A1 |
20030125729 | Hooven et al. | Jul 2003 | A1 |
20030130598 | Manning et al. | Jul 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030204161 | Ferek Petric | Oct 2003 | A1 |
20030229379 | Ramsey | Dec 2003 | A1 |
20040039382 | Kroll et al. | Feb 2004 | A1 |
20040049181 | Stewart et al. | Mar 2004 | A1 |
20040049182 | Koblish et al. | Mar 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040082948 | Stewart et al. | Apr 2004 | A1 |
20040087939 | Eggers et al. | May 2004 | A1 |
20040111087 | Stern et al. | Jun 2004 | A1 |
20040199157 | Palanker et al. | Oct 2004 | A1 |
20040236360 | Cohn et al. | Nov 2004 | A1 |
20040254607 | Wittenberger et al. | Dec 2004 | A1 |
20040267337 | Hayzelden | Dec 2004 | A1 |
20050033282 | Hooven | Feb 2005 | A1 |
20050222632 | Obino | Oct 2005 | A1 |
20050251130 | Boveja et al. | Nov 2005 | A1 |
20050261672 | Deem et al. | Nov 2005 | A1 |
20060009755 | Sra | Jan 2006 | A1 |
20060015095 | Desinger et al. | Jan 2006 | A1 |
20060015165 | Bertolero et al. | Jan 2006 | A1 |
20060024359 | Walker et al. | Feb 2006 | A1 |
20060058781 | Long | Mar 2006 | A1 |
20060111702 | Oral et al. | May 2006 | A1 |
20060142801 | Demarais et al. | Jun 2006 | A1 |
20060167448 | Kozel | Jul 2006 | A1 |
20060217703 | Chornenky et al. | Sep 2006 | A1 |
20060241734 | Marshall et al. | Oct 2006 | A1 |
20060264752 | Rubinsky et al. | Nov 2006 | A1 |
20060270900 | Chin et al. | Nov 2006 | A1 |
20060287648 | Schwartz | Dec 2006 | A1 |
20060293730 | Rubinsky et al. | Dec 2006 | A1 |
20060293731 | Rubinsky et al. | Dec 2006 | A1 |
20070005053 | Dando | Jan 2007 | A1 |
20070021744 | Creighton | Jan 2007 | A1 |
20070066972 | Ormsby et al. | Mar 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070156135 | Rubinsky et al. | Jul 2007 | A1 |
20070167740 | Grunewald et al. | Jul 2007 | A1 |
20070167940 | Stevens-Wright | Jul 2007 | A1 |
20070173878 | Heuser | Jul 2007 | A1 |
20070208329 | Ward et al. | Sep 2007 | A1 |
20070225589 | Viswanathan | Sep 2007 | A1 |
20070249923 | Keenan | Oct 2007 | A1 |
20070260223 | Scheibe et al. | Nov 2007 | A1 |
20070270792 | Hennemann et al. | Nov 2007 | A1 |
20080009855 | Hamou | Jan 2008 | A1 |
20080033426 | Machell | Feb 2008 | A1 |
20080065061 | Viswanathan | Mar 2008 | A1 |
20080086120 | Mirza | Apr 2008 | A1 |
20080091195 | Silwa et al. | Apr 2008 | A1 |
20080103545 | Bolea et al. | May 2008 | A1 |
20080132885 | Rubinsky et al. | Jun 2008 | A1 |
20080161789 | Thao et al. | Jul 2008 | A1 |
20080172048 | Martin et al. | Jul 2008 | A1 |
20080200913 | Viswanathan | Aug 2008 | A1 |
20080208118 | Goldman | Aug 2008 | A1 |
20080243214 | Koblish | Oct 2008 | A1 |
20080281322 | Sherman et al. | Nov 2008 | A1 |
20080300574 | Belson et al. | Dec 2008 | A1 |
20080300588 | Groth et al. | Dec 2008 | A1 |
20090024084 | Khosla et al. | Jan 2009 | A1 |
20090062788 | Long et al. | Mar 2009 | A1 |
20090076500 | Azure | Mar 2009 | A1 |
20090105654 | Kurth et al. | Apr 2009 | A1 |
20090149917 | Whitehurst et al. | Jun 2009 | A1 |
20090163905 | Winkler et al. | Jun 2009 | A1 |
20090228003 | Sinelnikov | Sep 2009 | A1 |
20090240248 | Deford et al. | Sep 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090281477 | Mikus et al. | Nov 2009 | A1 |
20090306651 | Schneider | Dec 2009 | A1 |
20100023004 | Francischelli et al. | Jan 2010 | A1 |
20100137861 | Soroff et al. | Jun 2010 | A1 |
20100185140 | Kassab et al. | Jul 2010 | A1 |
20100185186 | Longoria | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100191232 | Boveda | Jul 2010 | A1 |
20100241185 | Mahapatra et al. | Sep 2010 | A1 |
20100261994 | Davalos et al. | Oct 2010 | A1 |
20100274238 | Klimovitch | Oct 2010 | A1 |
20100280513 | Juergen et al. | Nov 2010 | A1 |
20100280539 | Miyoshi et al. | Nov 2010 | A1 |
20100292687 | Kauphusman et al. | Nov 2010 | A1 |
20100312300 | Ryu et al. | Dec 2010 | A1 |
20110028962 | Werneth et al. | Feb 2011 | A1 |
20110028964 | Edwards | Feb 2011 | A1 |
20110098694 | Long | Apr 2011 | A1 |
20110106221 | Neal, II et al. | May 2011 | A1 |
20110130708 | Perry et al. | Jun 2011 | A1 |
20110144524 | Fish et al. | Jun 2011 | A1 |
20110144633 | Govari | Jun 2011 | A1 |
20110160785 | Mori et al. | Jun 2011 | A1 |
20110190659 | Long et al. | Aug 2011 | A1 |
20110190727 | Edmunds et al. | Aug 2011 | A1 |
20110213231 | Hall et al. | Sep 2011 | A1 |
20110276047 | Sklar et al. | Nov 2011 | A1 |
20110276075 | Fung et al. | Nov 2011 | A1 |
20110288544 | Verin et al. | Nov 2011 | A1 |
20110313417 | De La Rama et al. | Dec 2011 | A1 |
20120029512 | Willard et al. | Feb 2012 | A1 |
20120046570 | Villegas et al. | Feb 2012 | A1 |
20120053581 | Wittkampf et al. | Mar 2012 | A1 |
20120059255 | Paul et al. | Mar 2012 | A1 |
20120071872 | Rubinsky et al. | Mar 2012 | A1 |
20120089089 | Swain et al. | Apr 2012 | A1 |
20120095459 | Callas et al. | Apr 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120158021 | Morrill | Jun 2012 | A1 |
20120165667 | Altmann et al. | Jun 2012 | A1 |
20120172859 | Condie et al. | Jul 2012 | A1 |
20120172867 | Ryu et al. | Jul 2012 | A1 |
20120197100 | Razavi et al. | Aug 2012 | A1 |
20120209260 | Lambert et al. | Aug 2012 | A1 |
20120220998 | Long et al. | Aug 2012 | A1 |
20120265198 | Crow et al. | Oct 2012 | A1 |
20120283582 | Mahapatra et al. | Nov 2012 | A1 |
20120303019 | Zhao et al. | Nov 2012 | A1 |
20120310052 | Mahapatra et al. | Dec 2012 | A1 |
20120310230 | Willis | Dec 2012 | A1 |
20120310237 | Swanson | Dec 2012 | A1 |
20120316557 | Sartor et al. | Dec 2012 | A1 |
20130030430 | Stewart et al. | Jan 2013 | A1 |
20130060247 | Sklar et al. | Mar 2013 | A1 |
20130060248 | Sklar et al. | Mar 2013 | A1 |
20130079768 | De Luca et al. | Mar 2013 | A1 |
20130090651 | Smith | Apr 2013 | A1 |
20130096655 | Moffitt et al. | Apr 2013 | A1 |
20130103027 | Sklar et al. | Apr 2013 | A1 |
20130103064 | Arenson et al. | Apr 2013 | A1 |
20130131662 | Wittkampf | May 2013 | A1 |
20130158538 | Govari | Jun 2013 | A1 |
20130172864 | Ibrahim et al. | Jul 2013 | A1 |
20130172875 | Govari et al. | Jul 2013 | A1 |
20130184702 | Neal, II et al. | Jul 2013 | A1 |
20130218157 | Callas et al. | Aug 2013 | A1 |
20130226174 | Ibrahim et al. | Aug 2013 | A1 |
20130237984 | Sklar | Sep 2013 | A1 |
20130253415 | Sano et al. | Sep 2013 | A1 |
20130296679 | Condie et al. | Nov 2013 | A1 |
20130310829 | Cohen | Nov 2013 | A1 |
20130317385 | Sklar et al. | Nov 2013 | A1 |
20130331831 | Werneth et al. | Dec 2013 | A1 |
20130338467 | Grasse et al. | Dec 2013 | A1 |
20140005664 | Govari et al. | Jan 2014 | A1 |
20140024911 | Harlev et al. | Jan 2014 | A1 |
20140039288 | Shih | Feb 2014 | A1 |
20140051993 | McGee | Feb 2014 | A1 |
20140052118 | Laske et al. | Feb 2014 | A1 |
20140052126 | Long et al. | Feb 2014 | A1 |
20140052216 | Long et al. | Feb 2014 | A1 |
20140081113 | Cohen et al. | Mar 2014 | A1 |
20140100563 | Govari et al. | Apr 2014 | A1 |
20140107644 | Falwell et al. | Apr 2014 | A1 |
20140142408 | De La Rama et al. | May 2014 | A1 |
20140163480 | Govari et al. | Jun 2014 | A1 |
20140163546 | Govari et al. | Jun 2014 | A1 |
20140171942 | Werneth et al. | Jun 2014 | A1 |
20140180035 | Anderson | Jun 2014 | A1 |
20140194716 | Diep et al. | Jul 2014 | A1 |
20140194867 | Fish et al. | Jul 2014 | A1 |
20140200567 | Cox et al. | Jul 2014 | A1 |
20140235986 | Harlev et al. | Aug 2014 | A1 |
20140235989 | Wodlinger et al. | Aug 2014 | A1 |
20140243851 | Cohen et al. | Aug 2014 | A1 |
20140276760 | Bonyak et al. | Sep 2014 | A1 |
20140276782 | Paskar | Sep 2014 | A1 |
20140276791 | Ku et al. | Sep 2014 | A1 |
20140288556 | Ibrahim et al. | Sep 2014 | A1 |
20140303721 | Fung et al. | Oct 2014 | A1 |
20140343549 | Spear et al. | Nov 2014 | A1 |
20140364845 | Rashidi | Dec 2014 | A1 |
20140371613 | Narayan et al. | Dec 2014 | A1 |
20150005767 | Werneth et al. | Jan 2015 | A1 |
20150011995 | Avitall et al. | Jan 2015 | A1 |
20150126840 | Thakur et al. | May 2015 | A1 |
20150133914 | Koblish | May 2015 | A1 |
20150138977 | Dacosta | May 2015 | A1 |
20150141978 | Subramaniam et al. | May 2015 | A1 |
20150142041 | Kendale et al. | May 2015 | A1 |
20150148796 | Bencini | May 2015 | A1 |
20150150472 | Harlev et al. | Jun 2015 | A1 |
20150157402 | Kunis et al. | Jun 2015 | A1 |
20150157412 | Wallace et al. | Jun 2015 | A1 |
20150164584 | Davalos et al. | Jun 2015 | A1 |
20150173824 | Davalos et al. | Jun 2015 | A1 |
20150173828 | Avitall | Jun 2015 | A1 |
20150174404 | Rousso et al. | Jun 2015 | A1 |
20150182740 | Mickelsen | Jul 2015 | A1 |
20150196217 | Harlev et al. | Jul 2015 | A1 |
20150223726 | Harlev et al. | Aug 2015 | A1 |
20150230699 | Berul et al. | Aug 2015 | A1 |
20150258344 | Tandri et al. | Sep 2015 | A1 |
20150265342 | Long et al. | Sep 2015 | A1 |
20150265344 | Aktas et al. | Sep 2015 | A1 |
20150272656 | Chen | Oct 2015 | A1 |
20150272664 | Cohen | Oct 2015 | A9 |
20150272667 | Govari et al. | Oct 2015 | A1 |
20150282729 | Harlev et al. | Oct 2015 | A1 |
20150289923 | Davalos et al. | Oct 2015 | A1 |
20150304879 | Dacosta | Oct 2015 | A1 |
20150320481 | Cosman et al. | Nov 2015 | A1 |
20150321021 | Tandri et al. | Nov 2015 | A1 |
20150342532 | Basu et al. | Dec 2015 | A1 |
20150343212 | Rousso et al. | Dec 2015 | A1 |
20150351836 | Prutchi | Dec 2015 | A1 |
20150359583 | Swanson | Dec 2015 | A1 |
20160000500 | Salahieh et al. | Jan 2016 | A1 |
20160008061 | Fung et al. | Jan 2016 | A1 |
20160008065 | Gliner et al. | Jan 2016 | A1 |
20160029960 | Toth et al. | Feb 2016 | A1 |
20160038772 | Thapliyal et al. | Feb 2016 | A1 |
20160051204 | Harlev et al. | Feb 2016 | A1 |
20160051324 | Stewart et al. | Feb 2016 | A1 |
20160058493 | Neal, II et al. | Mar 2016 | A1 |
20160058506 | Spence et al. | Mar 2016 | A1 |
20160066993 | Avitall et al. | Mar 2016 | A1 |
20160074679 | Thapliyal et al. | Mar 2016 | A1 |
20160095531 | Narayan et al. | Apr 2016 | A1 |
20160095642 | Deno et al. | Apr 2016 | A1 |
20160095653 | Lambert et al. | Apr 2016 | A1 |
20160100797 | Mahapatra et al. | Apr 2016 | A1 |
20160100884 | Fay et al. | Apr 2016 | A1 |
20160106498 | Highsmith et al. | Apr 2016 | A1 |
20160106500 | Olson | Apr 2016 | A1 |
20160113709 | Maor | Apr 2016 | A1 |
20160113712 | Cheung et al. | Apr 2016 | A1 |
20160120564 | Kirkpatrick et al. | May 2016 | A1 |
20160128770 | Afonso et al. | May 2016 | A1 |
20160166167 | Narayan et al. | Jun 2016 | A1 |
20160166310 | Stewart et al. | Jun 2016 | A1 |
20160166311 | Long et al. | Jun 2016 | A1 |
20160174865 | Stewart et al. | Jun 2016 | A1 |
20160184003 | Srimathveeravalli et al. | Jun 2016 | A1 |
20160213282 | Leo et al. | Jul 2016 | A1 |
20160220307 | Miller et al. | Aug 2016 | A1 |
20160235470 | Callas et al. | Aug 2016 | A1 |
20160287314 | Arena et al. | Oct 2016 | A1 |
20160310211 | Long | Oct 2016 | A1 |
20160324564 | Gerlach et al. | Nov 2016 | A1 |
20160324573 | Mickelsen et al. | Nov 2016 | A1 |
20160331441 | Konings | Nov 2016 | A1 |
20160331459 | Townley et al. | Nov 2016 | A1 |
20160354142 | Pearson et al. | Dec 2016 | A1 |
20160361109 | Weaver et al. | Dec 2016 | A1 |
20170035499 | Stewart et al. | Feb 2017 | A1 |
20170042449 | Deno et al. | Feb 2017 | A1 |
20170042615 | Salahieh et al. | Feb 2017 | A1 |
20170056648 | Syed et al. | Mar 2017 | A1 |
20170065330 | Mickelsen et al. | Mar 2017 | A1 |
20170065339 | Mickelsen | Mar 2017 | A1 |
20170065340 | Long | Mar 2017 | A1 |
20170065343 | Mickelsen | Mar 2017 | A1 |
20170071543 | Basu et al. | Mar 2017 | A1 |
20170095291 | Harrington et al. | Apr 2017 | A1 |
20170105793 | Cao et al. | Apr 2017 | A1 |
20170151029 | Mickelsen | Jun 2017 | A1 |
20170172654 | Wittkampf et al. | Jun 2017 | A1 |
20170181795 | Debruyne | Jun 2017 | A1 |
20170189097 | Viswanathan et al. | Jul 2017 | A1 |
20170215953 | Long et al. | Aug 2017 | A1 |
20170245928 | Xiao et al. | Aug 2017 | A1 |
20170246455 | Athos et al. | Aug 2017 | A1 |
20170312024 | Harlev et al. | Nov 2017 | A1 |
20170312025 | Harlev et al. | Nov 2017 | A1 |
20170312027 | Harlev et al. | Nov 2017 | A1 |
20180001056 | Leeflang et al. | Jan 2018 | A1 |
20180042674 | Mickelsen | Feb 2018 | A1 |
20180042675 | Long | Feb 2018 | A1 |
20180064488 | Long et al. | Mar 2018 | A1 |
20180085160 | Viswanathan et al. | Mar 2018 | A1 |
20180093088 | Mickelsen | Apr 2018 | A1 |
20180200497 | Mickelsen | Jul 2018 | A1 |
20180303488 | Hill | Oct 2018 | A1 |
20180311497 | Viswanathan et al. | Nov 2018 | A1 |
20180360534 | Teplitsky et al. | Dec 2018 | A1 |
20190069950 | Viswanathan et al. | Mar 2019 | A1 |
Number | Date | Country |
---|---|---|
1125549 | Aug 2001 | EP |
0797956 | Jun 2003 | EP |
1127552 | Jun 2006 | EP |
1340469 | Mar 2007 | EP |
1009303 | Jun 2009 | EP |
2213729 | Aug 2010 | EP |
2425871 | Mar 2012 | EP |
1803411 | Aug 2012 | EP |
2532320 | Dec 2012 | EP |
2587275 | May 2013 | EP |
2663227 | Nov 2013 | EP |
1909678 | Jan 2014 | EP |
2217165 | Mar 2014 | EP |
2376193 | Mar 2014 | EP |
2708181 | Mar 2014 | EP |
2777579 | Sep 2014 | EP |
2934307 | Oct 2015 | EP |
2777585 | Jun 2016 | EP |
2382935 | Mar 2018 | EP |
3111871 | Mar 2018 | EP |
3151773 | Apr 2018 | EP |
H06-507797 | Sep 1994 | JP |
2000-508196 | Jul 2000 | JP |
2005-516666 | Jun 2005 | JP |
2006-506184 | Feb 2006 | JP |
2008-538997 | Nov 2008 | JP |
2009-500129 | Jan 2009 | JP |
2011-509158 | Mar 2011 | JP |
2012-050538 | Mar 2012 | JP |
WO 9207622 | May 1992 | WO |
WO 9221278 | Dec 1992 | WO |
WO 9221285 | Dec 1992 | WO |
WO 9724073 | Jul 1997 | WO |
WO 9737719 | Oct 1997 | WO |
WO 1999004851 | Feb 1999 | WO |
WO 1999022659 | May 1999 | WO |
WO 2002056782 | Jul 2002 | WO |
WO 2003065916 | Aug 2003 | WO |
WO 2004045442 | Jun 2004 | WO |
WO 2004086994 | Oct 2004 | WO |
WO 2006115902 | Nov 2006 | WO |
WO 2007006055 | Jan 2007 | WO |
WO 2007079438 | Jul 2007 | WO |
WO 2009082710 | Jul 2009 | WO |
WO 2009089343 | Jul 2009 | WO |
WO 2009137800 | Nov 2009 | WO |
WO 2010014480 | Feb 2010 | WO |
WO 2011028310 | Mar 2011 | WO |
WO 2011154805 | Dec 2011 | WO |
WO 2012051433 | Apr 2012 | WO |
WO 2012153928 | Nov 2012 | WO |
WO 2013019385 | Feb 2013 | WO |
WO 2014025394 | Feb 2014 | WO |
WO 2014031800 | Feb 2014 | WO |
WO 2014160832 | Oct 2014 | WO |
WO 2015066322 | May 2015 | WO |
WO 2015099786 | Jul 2015 | WO |
WO 2015103530 | Jul 2015 | WO |
WO 2015103574 | Jul 2015 | WO |
WO 2015130824 | Sep 2015 | WO |
WO 2015143327 | Sep 2015 | WO |
WO 2015171921 | Nov 2015 | WO |
WO 2015175944 | Nov 2015 | WO |
WO 2015192018 | Dec 2015 | WO |
WO 2015192027 | Dec 2015 | WO |
WO 2016059027 | Apr 2016 | WO |
WO 2016060983 | Apr 2016 | WO |
WO 2016081650 | May 2016 | WO |
WO 2016090175 | Jun 2016 | WO |
WO 2017120169 | Jul 2017 | WO |
WO 2017192477 | Nov 2017 | WO |
WO 2017192495 | Nov 2017 | WO |
WO 2017218734 | Dec 2017 | WO |
Entry |
---|
Partial Supplementary European Search Report for European Application No. 13827672.0, dated Mar. 23, 2016, 6 pages. |
Supplementary European Search Report for European Application No. 13827672.0, dated Jul. 11, 2016, 12 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2015-526522, dated Mar. 6, 2017, 3 pages. |
Office Action for U.S. Appl. No. 14/400,455, dated Mar. 30, 2017, 10 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/031252, dated Jul. 19, 2013, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/010138, dated Mar. 26, 2015, 14 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2015/010138, dated Jul. 12, 2016, 9 pages. |
Supplementary European Search Report for European Application No. 15733297.4, dated Aug. 10, 2017, 7 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Apr. 3, 2017, 6 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Aug. 29, 2017, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/010223, dated Apr. 10, 2015, 19 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2017/012099, dated May 18, 2017, 17 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2015/010223, dated Jul. 12, 2016, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/029734, dated Nov. 24, 2015, 15 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/031086, dated Oct. 21, 2015, 16 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/055105, dated Mar. 1, 2016, 15 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/035582, dated Oct. 2, 2015, 17 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/035592, dated Oct. 2, 2015, 13 pages. |
Office Action for U.S. Appl. No. 15/334,646, dated Jul. 25, 2017, 19 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2016/057664, dated Feb. 24, 2017, 11 pages. |
Du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013). |
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages. |
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007]. |
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016). |
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014). |
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014). |
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014). |
Van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014). |
Van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015). |
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012). |
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011). |
Office Action for U.S. Appl. No. 15/334,646, dated Nov. 16, 2017, 26 pages. |
Office Action for U.S. Appl. No. 15/795,062, dated Dec. 19, 2017, 14 pages. |
Office Action for U.S. Appl. No. 15/795,075, dated Feb. 6, 2018, 9 pages. |
Office Action for U.S. Appl. No. 15/796,255, dated Jan. 10, 2018, 12 pages. |
Office Action for U.S. Appl. No. 15/672,916, dated Feb. 13, 2018, 16 pages. |
Office Action for U.S. Appl. No. 15/499,804, dated Jan. 3, 2018, 20 pages. |
Office Action for U.S. Appl. No. 15/794,717, dated Feb. 1, 2018, 10 pages. |
Office Action for European Application No. 13827672.0, dated Feb. 5, 2018, 6 pages. |
Office Action for U.S. Appl. No. 15/819,726, dated Jun. 4, 2018, 17 pages. |
Office Action for U.S. Appl. No. 15/917,194, dated Jun. 4, 2018, 17 pages. |
Office Action for U.S. Appl. No. 15/917,194, dated Oct. 9, 2018, 13 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2016-544072, dated Oct. 1, 2018, 6 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Jul. 12, 2018, 12 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Dec. 17, 2018, 17 pages. |
Office Action for U.S. Appl. No. 15/795,062, dated Apr. 9, 2018, 20 pages. |
Office Action for U.S. Appl. No. 15/341,523, dated Jan. 29, 2019, 10 pages. |
Office Action for U.S. Appl. No. 15/795,075, dated Jun. 15, 2018, 10 pages. |
Extended European Search Report for European Application No. 15849844.4, dated May 3, 2018, 8 pages. |
Office Action for U.S. Appl. No. 15/711,266, dated Feb. 23, 2018, 14 pages. |
Office Action for U.S. Appl. No. 15/672,916, dated Jul. 20, 2018, 23 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/029552, dated Jun. 29, 2018, 13 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/050660, dated Nov. 26, 2018, 13 pages. |
Office Action for U.S. Appl. No. 15/970,404, dated Oct. 9, 2018, 21 pages. |
Office Action for Japanese Application No. 2018-036714, dated Jan. 16, 2019, 8 pages. |
First Office Action for Chinese Application No. 201580006848.8, dated Jan. 29, 2018, 15 pages. |
Office Action for European Application No. 15701856.5, dated Dec. 11, 2017, 6 pages. |
Office Action for U.S. Appl. No. 15/201,983, dated Apr. 3, 2019, 16 pages. |
Extended European Search Report for European Application No. 15806855.1, dated Jan. 3, 2018, 8 pages. |
Extended European Search Report for European Application No. 15806278.6, dated Feb. 9, 2018, 5 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/029938, dated Aug. 29, 2018, 14 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2017/037609, dated Nov. 8, 2017, 13 pages. |
Partial European Search Report for European Application No. 18170210.1, dated Feb. 14, 2019, 13 pages. |
Number | Date | Country | |
---|---|---|---|
20180043153 A1 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
62274926 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15334646 | Oct 2016 | US |
Child | 15796375 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2016/057664 | Oct 2016 | US |
Child | 15334646 | US |